Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2017 Summary According to the recently published report 'Lysine Specific Histone Demethylase 1A - Pipeline Review, H2 2017'; Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) pipeline Target constitutes close to 20 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Lysine-specific histone demethylase 1A (KDM1A) also known as lysine (K)-specific demethylase 1A (LSD1) is a protein in encoded by the KDM1A gene. LSD1 specifically demethylates mono- or dimethylated dimethylated histone H3 lysine4 (H3K4) and H3 lysine 9 (H3K9) via a redox process. LSD1 played an important role in a broad spectrum of biological processes, including cell proliferation, adipogenesis, spermatogenesis, chromosome segregation and embryonic development. The report 'Lysine Specific Histone Demethylase 1A - Pipeline Review, H2 2017' outlays comprehensive information on the Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders, Other Diseases, Immunology, Infectious Disease and Metabolic Disorders which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Small-Cell Lung Cancer, Ewing Sarcoma, Myelodysplastic Syndrome, Alzheimer's Disease, Breast Cancer, Orphan Diseases, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sickle Cell Disease, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Promyelocytic Leukemia, Autoimmune Disorders, Dementia, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Huntington Disease, Leukemias, Lymphoma, Melanoma, Metastatic Breast Cancer, Multiple Sclerosis, Myelofibrosis, Neuroendocrine Carcinoma, Non-Hodgkin Lymphoma, Obesity, Parkinson's Disease, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Solid Tumor, Type 2 Diabetes and Viral Infections. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - The report reviews Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics and enlists all their major and minor projects - The report assesses Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Overview 8 Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Therapeutics Development 9 Products under Development by Stage of Development 9 Products under Development by Therapy Area 10 Products under Development by Indication 11 Products under Development by Companies 14 Products under Development by Universities/Institutes 18 Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Therapeutics Assessment 20 Assessment by Mechanism of Action 20 Assessment by Route of Administration 21 Assessment by Molecule Type 22 Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Companies Involved in Therapeutics Development 24 4SC AG 24 Beactica AB 24 Celgene Corp 25 GlaxoSmithKline Plc 25 Incyte Corp 26 Mirati Therapeutics Inc 27 Oryzon Genomics SA 27 Takeda Pharmaceutical Co Ltd 28 Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Drug Profiles 29 4SC-202 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 CC-90011 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Drugs to Inhibit KDM1A and PRKCQ for Metastatic Breast Cancer - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 GSK-2879552 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 IMG-7289 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 INCB-59872 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 ORY-2001 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 ORY-3001 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 RASP-201 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 RN-1 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecule to Inhibit LSD1 for Small Cell Lung Cancer and Acute Myelocytic Leukemia - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecules for Oncology - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Small Molecules to Inhibit LSD-1 for Oncology - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Small Molecules to Inhibit LSD1 for Alzheimer's Disease, Oncology and Viral Infections - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Small Molecules to Inhibit LSD1 for Glioblastoma Multiforme - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Small Molecules to Inhibit LSD1 for Obesity and Type 2 Diabetes - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 SP-2509 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 SP-2577 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Synthetic Peptide to Inhibit LSD-1 for Oncology - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 T-3775440 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Dormant Products 54 Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Discontinued Products 56 Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Product Development Milestones 57 Featured News & Press Releases 57 Sep 19, 2017: Imago BioSciences Doses First Patients in Phase 1/2 Study of IMG-7289 in Myelofibrosis 57 Jul 24, 2017: ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimer's Association International Conference (AAIC-2017) 57 Jul 19, 2017: Imago BioSciences Doses First Patients in the Phase 2a Portion of the Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome 58 Apr 24, 2017: ORYZON Announces New Grant from Alzheimer's Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug 59 Apr 11, 2017: New mechanistic insights into 4SC-202's epigenetic mode of action 60 Apr 03, 2017: ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer's and Parkinson's diseases 60 Feb 27, 2017: ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017 61 Feb 20, 2017: ORYZON to present ORY-2001 new preclinical data of therapeutic activity at ACTRIMS-2017 in Orlando, Fl. USA 63 Jan 30, 2017: Oryzon Genomics Will Present ORY-2001 at Keystone Symposia on Epigenetics and Human Disease 63 Jan 25, 2017: ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria 64 Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board 65 Jan 05, 2017: Mirati Therapeutics Provides Update On Cancer Pre-Clinical Program 65 Nov 08, 2016: Imago BioSciences Enrolls First Patient in Phase 1/2 Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome 66 Sep 12, 2016: Oryzon to Present ORY-2001 Preclinical Efficacy Data in Multiple Sclerosis Animal Model at ECTRIMS-2016 Annual Meeting 66 Jul 27, 2016: Oryzon Initiates Multiple Ascending Dose Cohorts in ORY-2001 Phase 1 Clinical Trial 67 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables
Number of Products under Development by Stage of Development, H2 2017 9 Number of Products under Development by Therapy Areas, H2 2017 10 Number of Products under Development by Indications, H2 2017 11 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13 Number of Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 15 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17 Number of Products under Investigation by Universities/Institutes, H2 2017 18 Products under Investigation by Universities/Institutes, H2 2017 19 Number of Products by Stage and Mechanism of Actions, H2 2017 20 Number of Products by Stage and Route of Administration, H2 2017 21 Number of Products by Stage and Molecule Type, H2 2017 23 Pipeline by 4SC AG, H2 2017 24 Pipeline by Beactica AB, H2 2017 25 Pipeline by Celgene Corp, H2 2017 25 Pipeline by GlaxoSmithKline Plc, H2 2017 26 Pipeline by Incyte Corp, H2 2017 26 Pipeline by Mirati Therapeutics Inc, H2 2017 27 Pipeline by Oryzon Genomics SA, H2 2017 27 Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 28 Dormant Products, H2 2017 54 Dormant Products, H2 2017 (Contd..1), H2 2017 55 Discontinued Products, H2 2017 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
